Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. more
Time Frame | SNGX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 3.44% | -2.82% | 0.15% |
1-Month Return | -9.32% | -4.22% | 1.78% |
3-Month Return | -3.5% | -9.52% | 8.7% |
6-Month Return | -10.54% | -3.45% | 12.24% |
1-Year Return | -67.11% | 5.62% | 30.9% |
3-Year Return | -98.16% | 3.8% | 30.19% |
5-Year Return | -98.89% | 39.68% | 91.72% |
10-Year Return | -99.9% | 105.02% | 203.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 4.63M | 2.36M | 824.27K | 948.91K | 839.36K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":50.96,"profit":true},{"date":"2021-12-31","value":17.8,"profit":true},{"date":"2022-12-31","value":20.5,"profit":true},{"date":"2023-12-31","value":18.13,"profit":true}] |
Cost of Revenue | 3.57M | 1.82M | 728.64K | 550.82K | 742.05K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":51.04,"profit":true},{"date":"2021-12-31","value":20.42,"profit":true},{"date":"2022-12-31","value":15.44,"profit":true},{"date":"2023-12-31","value":20.8,"profit":true}] |
Gross Profit | 1.06M | 538.50K | 95.63K | 398.09K | 97.31K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":50.68,"profit":true},{"date":"2021-12-31","value":9,"profit":true},{"date":"2022-12-31","value":37.47,"profit":true},{"date":"2023-12-31","value":9.16,"profit":true}] |
Gross Margin | 22.95% | 22.82% | 11.60% | 41.95% | 11.59% | [{"date":"2019-12-31","value":54.7,"profit":true},{"date":"2020-12-31","value":54.4,"profit":true},{"date":"2021-12-31","value":27.65,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":27.64,"profit":true}] |
Operating Expenses | 11.17M | 19.03M | 13.06M | 14.50M | 7.80M | [{"date":"2019-12-31","value":58.7,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":68.64,"profit":true},{"date":"2022-12-31","value":76.22,"profit":true},{"date":"2023-12-31","value":40.96,"profit":true}] |
Operating Income | (10.11M) | (18.49M) | (12.97M) | (14.11M) | (7.70M) | [{"date":"2019-12-31","value":-1010742700,"profit":false},{"date":"2020-12-31","value":-1849114800,"profit":false},{"date":"2021-12-31","value":-1296611500,"profit":false},{"date":"2022-12-31","value":-1410603500,"profit":false},{"date":"2023-12-31","value":-769794000,"profit":false}] |
Total Non-Operating Income/Expense | 290.13K | 50.21K | (1.31M) | (1.54M) | (488.83K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":17.31,"profit":true},{"date":"2021-12-31","value":-452.28,"profit":false},{"date":"2022-12-31","value":-529.76,"profit":false},{"date":"2023-12-31","value":-168.49,"profit":false}] |
Pre-Tax Income | (9.97M) | (18.53M) | (13.42M) | (14.95M) | (7.91M) | [{"date":"2019-12-31","value":-996626800,"profit":false},{"date":"2020-12-31","value":-1852541500,"profit":false},{"date":"2021-12-31","value":-1341571500,"profit":false},{"date":"2022-12-31","value":-1495327400,"profit":false},{"date":"2023-12-31","value":-790853300,"profit":false}] |
Income Taxes | (610.68K) | (836.89K) | (864.74K) | (1.15M) | (1.77M) | [{"date":"2019-12-31","value":-61067600,"profit":false},{"date":"2020-12-31","value":-83689300,"profit":false},{"date":"2021-12-31","value":-86474200,"profit":false},{"date":"2022-12-31","value":-115493500,"profit":false},{"date":"2023-12-31","value":-176780300,"profit":false}] |
Income After Taxes | (9.36M) | (17.69M) | (12.55M) | (13.80M) | (6.14M) | [{"date":"2019-12-31","value":-935559200,"profit":false},{"date":"2020-12-31","value":-1768852200,"profit":false},{"date":"2021-12-31","value":-1255097300,"profit":false},{"date":"2022-12-31","value":-1379833900,"profit":false},{"date":"2023-12-31","value":-614073000,"profit":false}] |
Income From Continuous Operations | (9.36M) | (17.69M) | (12.55M) | (13.80M) | (8.07M) | [{"date":"2019-12-31","value":-935559200,"profit":false},{"date":"2020-12-31","value":-1768852200,"profit":false},{"date":"2021-12-31","value":-1255097300,"profit":false},{"date":"2022-12-31","value":-1379833900,"profit":false},{"date":"2023-12-31","value":-807439000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (9.36M) | (17.69M) | (12.55M) | (13.80M) | (6.14M) | [{"date":"2019-12-31","value":-935559200,"profit":false},{"date":"2020-12-31","value":-1768852200,"profit":false},{"date":"2021-12-31","value":-1255097300,"profit":false},{"date":"2022-12-31","value":-1379833900,"profit":false},{"date":"2023-12-31","value":-614073000,"profit":false}] |
EPS (Diluted) | (7.35) | (9.60) | (4.65) | (8.18) | (0.97) | [{"date":"2019-12-31","value":-735,"profit":false},{"date":"2020-12-31","value":-960,"profit":false},{"date":"2021-12-31","value":-465,"profit":false},{"date":"2022-12-31","value":-818,"profit":false},{"date":"2023-12-31","value":-97,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SNGX | |
---|---|
Cash Ratio | 2.17 |
Current Ratio | 2.28 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SNGX | |
---|---|
ROA (LTM) | -45.14% |
ROE (LTM) | -139.80% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SNGX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.43 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.57 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SNGX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 23.88 |
P/B | 1.47 |
Price/FCF | NM |
EV/R | 1.87 |
EV/Ebitda | NM |
PEG | NM |
Soligenix Inc (SNGX) share price today is $3.31
Yes, Indians can buy shares of Soligenix Inc (SNGX) on Vested. To buy Soligenix Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SNGX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Soligenix Inc (SNGX) via the Vested app. You can start investing in Soligenix Inc (SNGX) with a minimum investment of $1.
You can invest in shares of Soligenix Inc (SNGX) via Vested in three simple steps:
The 52-week high price of Soligenix Inc (SNGX) is $19.2. The 52-week low price of Soligenix Inc (SNGX) is $1.83.
The price-to-earnings (P/E) ratio of Soligenix Inc (SNGX) is
The price-to-book (P/B) ratio of Soligenix Inc (SNGX) is 1.47
The dividend yield of Soligenix Inc (SNGX) is 0.00%
The market capitalization of Soligenix Inc (SNGX) is $8.76M
The stock symbol (or ticker) of Soligenix Inc is SNGX